New drug targets specific cancer mutation in patients out of options
NCT ID NCT04439123
Summary
This study is testing an experimental drug called AZD5363 in patients with advanced cancers that have a specific genetic change called an AKT mutation. The drug is designed to block the AKT protein, which cancer cells need to grow. Researchers want to see if taking this pill can shrink these hard-to-treat tumors or stop them from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.